Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Efficacy and Safety Results of the Phase 3 Candor Study

Meletios A Dimopoulos, Hang Quach, MDFRACP,FRCPA,MBBS, María-Victoria Mateos, Ola Landgren, MD PhD, Xavier Leleu, MD, David S. Siegel, MD PhD, Katja Weisel, MD, Maria Gavriatopoulou, Albert Oriol, MD, Neil K Rabin, Ajay Nooka, MDMPH, Ming Qi, MD PhD, Bifeng Ding, Anita Zahlten-Kumeli, Saad Z. Usmani, MDMBBS,MBA

Blood (2020) 136 (Supplement 1): 26–27.

https://doi.org/10.1182/blood-2020-137602

Published: 2020

Journal Articles

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor (NCT03158688)

Saad Z. Usmani, MDMBBS, Hang Quach, MD, María-Victoria Mateos, Ola Landgren, MD PhD, Xavier Leleu, MD PhD, David S. Siegel, Katja Weisel, Hui Yang, Zandra K. Klippel, MD, Anita Zahlten-Kumeli, Meletios A. Dimopoulos, MD

Blood (2019) 134 (Supplement_2): LBA-6.

https://doi.org/10.1182/blood-2019-132629

Published: 2019

Journal Articles

Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma

Thierry Facon, Jae Hoon Lee, Philippe Moreau, Ruben Niesvizky, Meletios Dimopoulos, Roman Hajek, Ludek Pour, Artur Jurczyszyn, Lugui Qiu, Zandra Klippel, Anita Zahlten-Kumeli, Muhtarjan Osman, Bruno Paiva, Jesus San-Miguel

Blood (2019) 133 (18): 1953–1963.

https://doi.org/10.1182/blood-2018-09-874396

Published: 2019

Includes: Supplemental data

Journal Articles

Efficacy and Safety of Once-Weekly vs Twice-Weekly Carfilzomib Plus Dexamethasone: Subgroup Analysis of the Phase 3 A.R.R.O.W. Study (NCT02412878) By Prior Lines

Philippe Moreau, A Keith Stewart, MB, ChB, Antonio Lazzaro, Meletios A Dimopoulos, MD, Michele Cavo, MD, Sikander Ailawadhi, Karim Iskander, Mei Huang, Anita Zahlten-Kumeli, Maria-Victoria Mateos, MD PhD

Blood (2018) 132 (Supplement 1): 3244.

https://doi.org/10.1182/blood-2018-99-114863

Published: 2018

Journal Articles

Efficacy and Safety of Carfilzomib and Dexamethasone in Lenalidomide Exposed and Refractory Multiple Myeloma Patients: Combined Analysis of Carfilzomib Trials

Maria-Victoria Mateos, MD PhD, Jesus G. Berdeja, MD, Meletios A Dimopoulos, MD, David S Siegel, MD PhD, P Joy Ho, MBBS(Syd) DPhil(Oxon) FRACP FRCPA FFSc(RCPA), Mei Huang, Martina Sersch, Anita Zahlten-Kumeli, Amy S Kimball, Katja Weisel, MD

Blood (2018) 132 (Supplement 1): 1963.

https://doi.org/10.1182/blood-2018-99-112600

Published: 2018

Journal Articles

Once Weekly Versus Twice Weekly Carfilzomib Dosing in Patients with Relapsed and Refractory Multiple Myeloma (A.R.R.O.W.): Efficacy and Safety Analyzed By Age Group

Meletios A Dimopoulos, MD, Ruben Niesvizky, MD, Philippe Moreau, David S Siegel, MD PhD, Roman Hajek, MD PhD, Maria-Victoria Mateos, MD PhD, Michele Cavo, MD, Mei Huang, Anita Zahlten-Kumeli, Katja Weisel, MD

Blood (2018) 132 (Supplement 1): 3277.

https://doi.org/10.1182/blood-2018-99-118448

Published: 2018

NARROW

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Efficacy and Safety Results of the Phase 3 Candor Study

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor (NCT03158688)

Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma

Efficacy and Safety of Once-Weekly vs Twice-Weekly Carfilzomib Plus Dexamethasone: Subgroup Analysis of the Phase 3 A.R.R.O.W. Study (NCT02412878) By Prior Lines

Efficacy and Safety of Carfilzomib and Dexamethasone in Lenalidomide Exposed and Refractory Multiple Myeloma Patients: Combined Analysis of Carfilzomib Trials

Once Weekly Versus Twice Weekly Carfilzomib Dosing in Patients with Relapsed and Refractory Multiple Myeloma (A.R.R.O.W.): Efficacy and Safety Analyzed By Age Group

Email alerts

ASH Publications

American Society of Hematology

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Efficacy and Safety Results of the Phase 3 Candor Study

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor (NCT03158688)

Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma

Efficacy and Safety of Once-Weekly vs Twice-Weekly Carfilzomib Plus Dexamethasone: Subgroup Analysis of the Phase 3 A.R.R.O.W. Study (NCT02412878) By Prior Lines

Efficacy and Safety of Carfilzomib and Dexamethasone in Lenalidomide Exposed and Refractory Multiple Myeloma Patients: Combined Analysis of Carfilzomib Trials

Once Weekly Versus Twice Weekly Carfilzomib Dosing in Patients with Relapsed and Refractory Multiple Myeloma (A.R.R.O.W.): Efficacy and Safety Analyzed By Age Group

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only